Clinical Oncology Education

The Invisible Barrier: Addressing the Dual Crisis of Immigration Status and Cancer Care the-invisible-barrier-addressing-the-dual-crisis-of-immigration-status-and-cancer-care-1

The Invisible Barrier: Addressing the Dual Crisis of Immigration Status and Cancer Care

Jia Lissa July 21, 2026

In the complex landscape of oncology, medical expertise is only one half of the equation. For the...

Redefining High-Risk Biochemically Recurrent Prostate Cancer: Insights from the EMBARK Trial redefining-high-risk-biochemically-recurrent-prostate-cancer-insights-from-the-embark-trial

Redefining High-Risk Biochemically Recurrent Prostate Cancer: Insights from the EMBARK Trial

Evan Lee Salim July 20, 2026

The management of high-risk biochemically recurrent (BCR) prostate cancer—a condition characterized by rising prostate-specific antigen (PSA) levels...

Revolutionizing Oncology: The Global Roll-Out of AI-Powered Bone Imaging for Advanced Cancer revolutionizing-oncology-the-global-roll-out-of-ai-powered-bone-imaging-for-advanced-cancer

Revolutionizing Oncology: The Global Roll-Out of AI-Powered Bone Imaging for Advanced Cancer

Ali Ikhwan July 17, 2026

In a landmark development for oncology and medical imaging, The Institute of Cancer Research (ICR), London, and...

FDA Expands Scope of Palbociclib: A New Maintenance Strategy for HR+/HER2+ Metastatic Breast Cancer fda-expands-scope-of-palbociclib-a-new-maintenance-strategy-for-hr-her2-metastatic-breast-cancer

FDA Expands Scope of Palbociclib: A New Maintenance Strategy for HR+/HER2+ Metastatic Breast Cancer

Iffa Jayyana July 17, 2026

In a significant development for oncology therapeutics, the U.S. Food and Drug Administration (FDA) has granted approval...

Breakthrough in Pediatric Oncology: Combining Radiopharmaceuticals and CAR T-Cell Therapy to Defeat Solid Tumors breakthrough-in-pediatric-oncology-combining-radiopharmaceuticals-and-car-t-cell-therapy-to-defeat-solid-tumors

Breakthrough in Pediatric Oncology: Combining Radiopharmaceuticals and CAR T-Cell Therapy to Defeat Solid Tumors

Basiran July 16, 2026

In a significant stride toward overcoming one of the most persistent hurdles in modern oncology, researchers at...

FDA Approves Subcutaneous Isatuximab-irfc: A New Era in Multiple Myeloma Treatment fda-approves-subcutaneous-isatuximab-irfc-a-new-era-in-multiple-myeloma-treatment

FDA Approves Subcutaneous Isatuximab-irfc: A New Era in Multiple Myeloma Treatment

Rifan Muazin July 16, 2026

The landscape of multiple myeloma (MM) management has undergone a significant evolution following the U.S. Food and...

A Paradigm Shift in Oncology: Revolutionary Brush Test Promises One-Hour Oral Cancer Detection a-paradigm-shift-in-oncology-revolutionary-brush-test-promises-one-hour-oral-cancer-detection

A Paradigm Shift in Oncology: Revolutionary Brush Test Promises One-Hour Oral Cancer Detection

Nana Wu July 16, 2026

In a landmark development for global oncology, researchers led by Queen Mary University of London have successfully...

Navigating the New Frontier: The Evolution of BCMA-Targeted Therapies in Multiple Myeloma navigating-the-new-frontier-the-evolution-of-bcma-targeted-therapies-in-multiple-myeloma

Navigating the New Frontier: The Evolution of BCMA-Targeted Therapies in Multiple Myeloma

Raul Delapena Setiawan July 15, 2026

The treatment landscape for multiple myeloma (MM) is currently undergoing its most significant paradigm shift since the...

The Biological Vulnerability: Defining the Critical Postpartum Window for Breast Cancer Risk the-biological-vulnerability-defining-the-critical-postpartum-window-for-breast-cancer-risk

The Biological Vulnerability: Defining the Critical Postpartum Window for Breast Cancer Risk

Azzam Bilal Chamdy July 15, 2026

New research from the UCLA Health Jonsson Comprehensive Cancer Centre has cast a significant light on the...

The Liquid Biopsy Revolution: Redefining Early-Stage Breast Cancer Surveillance Through MRD Testing the-liquid-biopsy-revolution-redefining-early-stage-breast-cancer-surveillance-through-mrd-testing

The Liquid Biopsy Revolution: Redefining Early-Stage Breast Cancer Surveillance Through MRD Testing

Azzam Bilal Chamdy July 15, 2026

The landscape of breast cancer management is undergoing a seismic shift. For decades, the standard of care...

Clinical Oncology Education

The Invisible Barrier: Addressing the Dual Crisis of Immigration Status and Cancer Care

Redefining High-Risk Biochemically Recurrent Prostate Cancer: Insights from the EMBARK Trial

Revolutionizing Oncology: The Global Roll-Out of AI-Powered Bone Imaging for Advanced Cancer

FDA Expands Scope of Palbociclib: A New Maintenance Strategy for HR+/HER2+ Metastatic Breast Cancer

Breakthrough in Pediatric Oncology: Combining Radiopharmaceuticals and CAR T-Cell Therapy to Defeat Solid Tumors

FDA Approves Subcutaneous Isatuximab-irfc: A New Era in Multiple Myeloma Treatment

A Paradigm Shift in Oncology: Revolutionary Brush Test Promises One-Hour Oral Cancer Detection

Navigating the New Frontier: The Evolution of BCMA-Targeted Therapies in Multiple Myeloma

The Biological Vulnerability: Defining the Critical Postpartum Window for Breast Cancer Risk

The Liquid Biopsy Revolution: Redefining Early-Stage Breast Cancer Surveillance Through MRD Testing

You may have missed

Beyond the Diagnosis: How Steve Garraty Transformed a Cancer Battle into a Life of Purpose

Beyond the Fold: How Talus Bio’s ‘Structure-Free’ AI Is Revolutionizing Drug Discovery

Bridging Generations: How Shanti Project’s Peer Support Model Redefines Chosen Family

Groundbreaking Oklahoma Research Unveils How Aggressive Breast Cancer Hijacks Immune System to Recruit Nerves, Fueling Growth